CIRIUS - Key Persons

Job Titles:

• Member of the Management Team
• Vice President, Development

Job Titles:

• Chief Business Officer
• Chief Financial Officer

Brian has over 20 years of experience in the healthcare industry and has held senior leadership positions in several pharmaceutical companies. He previously co-founded and served as chief business officer of Hawkeye Therapeutics and served as chief business officer at Laguna Pharmaceuticals and as vice president of corporate development and operations at Sequel Pharmaceuticals. Prior to Sequel, he was responsible for corporate development at NovaCardia until its acquisition by Merck & Co., Inc., in 2007. Before this, he was a global marketing associate at Eli Lilly and worked in marketing and sales operations for Prudential HealthCare and in public health program management. Brian is also an entrepreneur-in-residence at Frazier Healthcare Partners. He earned his M.B.A. from the University of Texas and his B.S. from Trinity University.

Job Titles:

• Chairman of the Board of Directors and Chief Executive Officer of the Van Andel Institute for Education
• Partner at Novo Ventures

Nilesh Kumar joined Cirius' board of directors since March 2017. Dr. Kumar has been a partner at Novo Ventures, a venture capital fund, since January 2017, and before that, a senior principle since April 2015. Prior to Novo Ventures, Dr. Kumar held various positions in the Merck KGaA family of companies since 2009, culminating in the position of senior investment director, where he led several venture investments and strategic licensing transactions in the field of oncology and autoimmune diseases. Dr. Kumar also serves on board of directors of Tarveda Therapeutics, Inc., Morphic Holding LLC, Milestone Pharmaceuticals, Inc., Rgenix, Inc., Anokion SA and Kanyos Bio Inc. Nilesh received his Ph.D. and MBA from Harvard University, and undergraduate degree from University of Cambridge, United Kingdom. David Van Andel has served on Cirius' board of directors since May 2016. Mr. Van Andel is the chairman of the board of directors and chief executive officer of the Van Andel Institute for Education and Medical Research, a biomedical research and science education organization, a position he has held since 1996. Mr. Van Andel has served on the board of directors of Twinlabs Consolidated Holdings, Inc., an integrated manufacturer, marketer, and distributor of branded nutritional supplements and other natural products since February 2015. Since September 1999, Mr. Van Andel has served on the board of directors of Amway Corporation and has held various positions at Amway Corporation since 1977, including senior vice president - operations, vice president of manufacturing and operations, and director of regional distribution centers. Mr. Van Andel received his B.A. in business administration from Hope College.

Dennis Fenton joined Cirius' board of directors since December 2017. Dr. Fenton has served on the board of directors of Sienna Biopharmaceuticals, Inc. since October 2016. From 1982 until his retirement in 2008, Dr. Fenton worked at Amgen, where he held positions of increasing responsibility, including vice president of research, senior vice president of sales and marketing, senior vice president of operations and executive vice president. Previously, Dr. Fenton worked as a researcher at Pfizer Central in new product development from 1977 to 1981. Dr. Fenton is currently an independent consultant and a member of the board of directors of Portola Pharmaceuticals, Inc., a public pharmaceutical company, Omniox, Inc., a biotechnology company and Modern Meadow, Inc. a private company. Dr. Fenton previously served on the board of directors of then-public life sciences companies Kythera Biopharmaceuticals, Inc., Hospira Inc., Dendreon Corp., Pfenex Inc., Xenoport, Inc. and Genzyme Corporation. He is also a member of the board of trustees of the Keck Graduate Institute. Dr. Fenton received a Ph.D. in microbiology from Rutgers University and a B.S. in biology from Manhattan College.

Elaine Sun has served on Cirius' board of directors since December 2018. Ms. Sun has over 20 years of experience as an investment banker in the life sciences industry and currently serves as senior vice president, chief financial officer of Halozyme, a biotechnology company focused on novel biological and drug delivery approaches and has held the position of chief financial officer since February 2020. Prior to her role as CFO Halozyme, Elaine was CFO at Sutrovax starting in January 2017. From January 2013 to December 2016, Ms. Sun served as a strategic and financial advisor to private equity, venture capital and venture-backed biotechnology companies. From 2009 to 2012, Ms. Sun served as managing director and head of west coast healthcare for Evercore Partners, an independent investment banking advisory firm. Prior to Evercore, Ms. Sun was a managing director at Merrill Lynch & Co. in the healthcare investment banking group, a position she held from 2005. From 1996 to 2004, Ms. Sun held positions of varying responsibilities at Merrill Lynch & Co., specializing in working with pharmaceutical, biotechnology and medical device companies on mergers and acquisitions, as well as equity, equity-linked and debt offerings. Ms. Sun received a B.A. in Economics and Japanese Studies from Wellesley College and an M.B.A from Harvard Business School.

Job Titles:

• Chief Medical Officer
• Adjunct Professor of Medicine at the University of Iowa Carver College of Medicine
• Cardiologist
• Vice President of Clinical Operations

Julie brings more than 25 years of experience guiding clinical development programs through the U.S. Food and Drug Administration clearance process. Previously, Julie served as executive director, clinical operations at Kodiak Sciences Inc., a now-public clinical biopharmaceutical company. Prior to Kodiak, she served as executive director of clinical development at Laguna and, prior to that, at Sorbent Therapeutics. Prior to Sorbent, Julie was senior director of clinical development at MAP Pharmaceuticals and held positions at Proteolix, through its acquisition by Onyx Pharmaceuticals, and at Affymax. She has also managed clinical programs at Genitope, Aviron (through acquisition by MedImmune), Amgen and Syntex in various therapeutic areas including renal, cardiovascular, and oncology. Julie holds a bachelor's degree in human biology from Stanford University. Howard is a cardiologist with more than 20 years of experience in cardiac therapeutic research and clinical development. He previously co-founded and served as the chief medical officer of Hawkeye Therapeutics and Sequel Pharmaceuticals. He served as chief medical officer for Laguna Pharmaceuticals and Sorbent Therapeutics. Prior to that, he served as chief medical officer at NovaCardia until its acquisition by Merck & Co., Inc. Howard is also an entrepreneur-in-residence at Frazier Healthcare Partners and serves as president and a member of the board of directors of Advanced Endovascular Therapeutics, Inc., a private biotechnology company that he co-founded. Howard is an adjunct professor of medicine at the University of Iowa Carver College of Medicine and chair of the board of directors of the François M. Abboud Cardiovascular Research Center. He previously served as a full-time faculty member of the department of medicine, and later, as a part-time clinical professor of medicine, at the University of California, San Diego. Howard received his M.D. from the University of Iowa Carver College of Medicine and a B.S. from the University of Iowa. He completed his residency in internal medicine and clinical fellowship in cardiology at the University of California, San Diego.

Job Titles:

• Chief Scientific Officer
• Member of the Management Team

Job Titles:

• Corporate Controller
• Vice President, Finance

John has over 17 years of experience in the healthcare and technology sectors and has held various finance and accounting roles at PvP Biologics, Laguna Pharmaceuticals, Cebix Incorporated, Sequel Pharmaceuticals, NovaCardia, Cabrellis Pharmaceuticals and Archimedes Technology Group. He graduated cum laude from the University of Arizona with a B.S. degree in finance and is a member of the American Institute of Certified Public Accountants and the California Society of CPAs.

Job Titles:

• Member of the Investment Team and a Partner With Frazier Healthcare Partners

Daniel Estes has served on Cirius' board of directors since March 2017. Since April 2011, Dr. Estes has been a member of the investment team and a partner with Frazier Healthcare Partners where he focuses on investments in both development-stage and commercial-stage pharmaceutical companies. Prior to joining Frazier Healthcare Partners, Dr. Estes served as a management consultant with McKinsey & Company's healthcare practice between 2008 and 2011. Dr. Estes also serves on the board of directors of Arcutis, Inc., Semnur Pharmaceuticals, Inc., Outpost Medicine, LLC and Sierra Oncology, Inc. Dr. Estes received his Ph.D. in Biomedical Engineering from the University of Michigan and his B.S. in Electrical Engineering from Stanford University.

Job Titles:

• Member of the Board of Directors of Vericel Corporation

Robert Zerbe has served on our board of directors since May 2016. Dr. Zerbe has served as a member of the board of directors of Vericel Corporation, a developer of patient-specific expanded cell therapies for severe diseases and conditions, since January 2006 and as chairman of the board of directors since October 2012. Until July 2016, Dr. Zerbe was the chief executive officer of QUATRx Pharmaceuticals Company, or QUATRx, a drug development company he co-founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with pharmaceutical companies including Eli Lilly and Company, from 1982 to 1993, and Pfizer (formerly Parke-Davis) from 1993 to 2000. During his tenure at Eli Lilly and Company, Dr. Zerbe's clinical research and development positions included managing director, Lilly Research Center U.K., and vice president of clinical investigation and regulatory affairs. He joined Parke-Davis in 1993, becoming senior vice president of worldwide clinical research and development. Dr. Zerbe has also served on the board of managers of Metabolic Solutions Development Company, LLC since 2015. Dr. Zerbe received his M.D. from the Indiana University School of Medicine, and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health.